In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lutonix: Back To The Future With Drug-Coated Balloons

Executive Summary

Drug-coated balloons were once thought to be an unnecessary innovation because of drug-eluting stents. With DES no longer seen as the panacea for vascular disease, balloons could re-emerge as the next major technology platform, and Lutonix is leading the race to bring them to the US market.

Related Content

Cardionovum: As DEBs Heat Up, Who Needs The US Market?
Device and Diagnostics Dealmaking Quarterly Statistics, Q4 2011
First Drug-Coated Balloon IDE: A Conversation With Lutonix CEO Dennis Wahr
Drug-Eluting Balloons: Promise Versus Practicalities
Drug-Eluting Balloons: Coming of Age in the Periphery
Invatec: Translating Global Success in Vascular Devices to the US Market
Drug-Eluting Balloons: New Route to Revascularization
B. Braun's Bet on Balloons

Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts